Cyclophosphamide induces differentiation of Th17 cells in cancer patients

Sophie Viaud; Caroline Flament; Mustapha Zoubir; Patricia Pautier; Axel LeCesne; Vincent Ribrag; Jean Charles Soria; Virginie Marty; Philippe Vielh; Caroline Robert; Nathalie Chaput; Laurence Zitvogel

doi:10.1158/0008-5472.CAN-10-1259

Cyclophosphamide induces differentiation of Th17 cells in cancer patients

Sophie Viaud, Caroline Flament, Mustapha Zoubir, Patricia Pautier, Axel LeCesne, Vincent Ribrag, Jean Charles Soria, Virginie Marty, Philippe Vielh, Caroline Robert, Nathalie Chaput, Laurence Zitvogel

Research output: Contribution to journal › Article › peer-review

148 Citations (Scopus)

Abstract

Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4⁺ T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients.

Original language	English
Pages (from-to)	661-665
Number of pages	5
Journal	Cancer Research
Volume	71
Issue number	3
DOIs	https://doi.org/10.1158/0008-5472.CAN-10-1259
Publication status	Published - 1 Feb 2011

Access to Document

10.1158/0008-5472.CAN-10-1259

Cite this

@article{968dec6c74b9497e8ef5b953e6d408f7,

title = "Cyclophosphamide induces differentiation of Th17 cells in cancer patients",

abstract = "Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4+ T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients.",

author = "Sophie Viaud and Caroline Flament and Mustapha Zoubir and Patricia Pautier and Axel LeCesne and Vincent Ribrag and Soria, {Jean Charles} and Virginie Marty and Philippe Vielh and Caroline Robert and Nathalie Chaput and Laurence Zitvogel",

year = "2011",

month = feb,

day = "1",

doi = "10.1158/0008-5472.CAN-10-1259",

language = "English",

volume = "71",

pages = "661--665",

journal = "Cancer Research",

issn = "0008-5472",

number = "3",

}

TY - JOUR

T1 - Cyclophosphamide induces differentiation of Th17 cells in cancer patients

AU - Viaud, Sophie

AU - Flament, Caroline

AU - Zoubir, Mustapha

AU - Pautier, Patricia

AU - LeCesne, Axel

AU - Ribrag, Vincent

AU - Soria, Jean Charles

AU - Marty, Virginie

AU - Vielh, Philippe

AU - Robert, Caroline

AU - Chaput, Nathalie

AU - Zitvogel, Laurence

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4+ T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients.

AB - Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4+ T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients.

UR - http://www.scopus.com/inward/record.url?scp=79551514818&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-1259

DO - 10.1158/0008-5472.CAN-10-1259

M3 - Article

C2 - 21148486

AN - SCOPUS:79551514818

SN - 0008-5472

VL - 71

SP - 661

EP - 665

JO - Cancer Research

JF - Cancer Research

IS - 3

ER -

Cyclophosphamide induces differentiation of Th17 cells in cancer patients

Abstract

Access to Document

Other files and links

Cite this